Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671483 · ClinicalTrials.gov registry record · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,088
- Enrollment target
- 20
- Study locations
NCT06671483 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 1,088 participants, above the 830-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06671483, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,088 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zasocitinib
- DRUG Active Comparator
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties (AARDS) - Aventura
- RASF- Clinical Research Center - Boca Raton
- Clinical Research of West Florida | Clearwater, FL - Clearwater
- GNP Research, LLC | Hollywood, FL - Cooper City
- Driven Research LLC - Coral Gables
- Tectum Medical Research - Davie
- Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research - Hialeah
- Bioresearch Partners - Miami
- HMD Research LLC - Orlando
California
- First OC Dermatology Research Inc. - Fountain Valley
- Purushotham & Akther Kotha MD - La Mesa
- Triwest Research Associates LLC - La Mesa
- The Cohen Medical Centers - Thousand Oaks
- Foothill Arthritis Clinic - Tujunga
- Medvin Clinical Research - Whittier
Arizona
- AARR- Chandler AZ - Chandler
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
Colorado
- Denver Arthritis Clinic | Denver, CO - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,088 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06671483
The ClinicalTrials.gov registry entry for NCT06671483 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,088 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 830-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (31% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06671483 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06671483 about?
NCT06671483 is a clinical study titled "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines". Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modif...
What is the current status of trial NCT06671483?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,088 participants. The study started on 2025-03-03. Estimated completion is 2028-01-28.
What conditions does trial NCT06671483 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT06671483?
The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG), Active Comparator (DRUG).
Who is sponsoring clinical trial NCT06671483?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671483 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.